Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

Clinical trial NCT07245394 · RECRUITING

Trial details

NCT number: NCT07245394
Sponsor: TIDHI Innovation Inc.
Status: RECRUITING
Study type: OBSERVATIONAL

Inflammatory Bowel Disease (IBD)Crohn Disease (CD)Ulcerative Colitis (UC)IBD-unclassified (IBD-U)

Start date: 2026-01-29
Primary completion: 2027-11-01
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.